A busy young mother switching from an injectable treatment*

Female in her mid-20s
Single mother
Student with 2 part-time jobs

All information is current as of March 2018.

Contributed by an MS Specialist
St. Michael’s Hospital, University of Toronto, Toronto, Canada

*This case is based on a single patient and may not be fully representative of the overall patient population.
To protect patient privacy, patient details have been modified.
REAL-WORLD CASE STUDY:

A young and busy female patient prescribed MAVENCLAD after experiencing disease activity on another DMT

Disease and treatment history

- Diagnosis of relapsing MS in 2014; started an injectable DMT
- Continued with same injectable DMT 2014–2017 except during pregnancy; restarted after experiencing 2 postpartum relapses
- Myelopathic episode (compression of spinal cord) in early 2018

Recent disease activity

- Relapses*: multiple relapses since 2017, while on treatment
- MRI (brain and C-spine, in 2018): multiple Gd+ lesions
- Disability progression: EDSS score 2.5 (limb ataxia, nystagmus, fatigue) from 1.0 in 2017

Treatment plan

- Completed initial DMT education and screening
- Started year 1 treatment with MAVENCLAD, with treatment cycles in month 1 and 2

Treatment follow-up and outcomes

- Follow-up after first treatment course (month 7): no increase in EDSS; Grade 1 lymphopenia after recovery from Grade 2. Lymphocyte count 0.9 × 10^9/L (nadir 0.6 × 10^9/L in month 5)\(^1\): no other notable AEs
- Started second course of treatment in year 2, with ongoing monitoring for AEs

Factors the healthcare provider considered

- Efficacy switch from another DMT
- Single parent who appreciates the convenient dosage but understands that monitoring and doctor visits are part of her treatment plan

All information is current as of March 2018. Any follow-up information is not currently available.

*Relapses defined per treating physician.
\(^1\)Graded according to the Common Terminology Criteria for Adverse Events (version 5.0): 1, <LLN-0.8 × 10^9/L; 2, <0.8–0.5 × 10^9/L.

AE: adverse event; DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale.
INDICATION
MAVENCLAD® (cladribine) tablets is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.

Limitations of Use: MAVENCLAD is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: MALIGNANCIES and RISK OF TERATOGENICITY

• Treatment with MAVENCLAD may increase the risk of malignancy. MAVENCLAD is contraindicated in patients with current malignancy. In patients with prior malignancy or with increased risk of malignancy, evaluate the benefits and risks of the use of MAVENCLAD on an individual patient basis. Follow standard cancer screening guidelines in patients treated with MAVENCLAD.

• MAVENCLAD is contraindicated for use in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception because of the potential for fetal harm. Malformations and embryolethality occurred in animals. Exclude pregnancy before the start of treatment with MAVENCLAD in females of reproductive potential. Advise females and males of reproductive potential to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course. Stop MAVENCLAD if the patient becomes pregnant.

CONTRAINDICATIONS

• Patients with current malignancy.

• Pregnant women, and women and men of reproductive potential who do not plan to use effective contraception during and for 6 months after the last dose in each treatment course. May cause fetal harm.

• Patients with human immunodeficiency virus (HIV).

• Patients with active chronic infections (e.g., hepatitis or tuberculosis).

• Patients with a history of hypersensitivity to cladribine.

• Women intending to breastfeed while taking MAVENCLAD tablets and for 10 days after the last dose.

WARNINGS AND PRECAUTIONS

• Malignancies: Treatment with MAVENCLAD may increase the risk of malignancy. After the completion of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years. In clinical studies, patients who received additional MAVENCLAD treatment within 2 years after the first 2 treatment courses had an increased incidence of malignancy. The risk of malignancy with reinitiating MAVENCLAD more than 2 years after the completion of 2 treatment courses has not been studied. Follow standard cancer screening guidelines in patients treated with MAVENCLAD.

• Risk of Teratogenicity: MAVENCLAD may cause fetal harm when administered to pregnant women. In females of reproductive potential, exclude pregnancy before initiation of each treatment course of MAVENCLAD and prevent by the use of effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose of each treatment course. Women who become pregnant during treatment with MAVENCLAD should discontinue treatment.

• Lymphopenia: MAVENCLAD causes a dose-dependent reduction in lymphocyte count. In clinical studies, 87% of MAVENCLAD-treated patients experienced lymphopenia. The lowest absolute lymphocyte counts occurred approximately 2 to 3 months after the start of each treatment course and were lower with each additional treatment course. Concomitant use of MAVENCLAD with hematotoxic drugs may increase the risk of adverse reactions because of the additive hematological effects. Monitor lymphocyte counts before and during treatment, periodically thereafter, and when clinically indicated.
TREATMENT INITIATION CONSIDERATIONS:

Assessments prior to starting each treatment course

- **Discuss standard cancer screening:** Follow age-appropriate screening, such as the American Cancer Society (ACS) guidelines, because of the risk of malignancies.* MAVENCLAD is contraindicated in patients with current malignancy.

- **Exclude pregnancy:** Exclude pregnancy prior to treatment with MAVENCLAD in females of reproductive potential. MAVENCLAD is contraindicated in pregnant women and in women and men of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose in each treatment course.

- **Obtain a complete blood count (CBC):** Obtain a CBC with differential including lymphocyte count. Lymphocytes must be:
  - within normal limits before initiating the first treatment course
  - at least 800 cells/µL before initiating the second treatment course

  If necessary, delay the second treatment course for up to 6 months so that lymphocytes recover to at least 800 cells/µL. If this recovery takes longer, the patient should not receive further treatment with MAVENCLAD.

- **Rule out latent or acute infections:** Consider a delay in MAVENCLAD treatment until any acute infection is fully controlled
  - Obtain a baseline (within 3 months) MRI prior to the first treatment course because of the risk of PML (progressive multifocal leukoencephalopathy)
  - Screen for tuberculosis: Delay treatment with MAVENCLAD until tuberculosis has been adequately treated
  - Screen for hepatitis B and C: MAVENCLAD is contraindicated in patients with active chronic infections
  - Exclude HIV infection: MAVENCLAD is contraindicated in patients with HIV

- **Confirm vaccinations and immunizations**
  - Check for immunity to varicella zoster virus: Consider vaccinating patients who are antibody-negative
  - Administer all immunizations according to immunization guidelines prior to starting MAVENCLAD: Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting MAVENCLAD. Please note that the COVID-19 mRNA and viral vector vaccines are not live-attenuated or live vaccines*.

- **Obtain liver function tests**

Ongoing monitoring

- **Follow standard cancer screening guidelines**

- **Obtain CBCs at 2 and 6 months after start of treatment:** If the lymphocyte count at month 2 is below 200 cells/µL, monitor monthly until month 6. Administer anti-herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter. Patients with lymphocyte counts below 500 cells per microliter should be monitored for signs and symptoms suggestive of infections, including herpes infections.

Additional considerations

- **Patients with prior malignancy or with increased risk of malignancy:** evaluate the benefits and risks of the use of MAVENCLAD on an individual patient basis.

- **Females of reproductive potential should prevent pregnancy by use of effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose in each treatment course**
  - Women using systemically acting hormonal contraceptives should add a barrier method during MAVENCLAD dosing and for at least 4 weeks after the last dose in each treatment course.

- MAVENCLAD is contraindicated in women intending to breastfeed on a MAVENCLAD treatment day and for 10 days after the last dose.

- Initiation of MAVENCLAD in patients currently receiving immunosuppressive or myelosuppressive therapy is not recommended.

Refer to the full Prescribing Information for a complete list of treatment considerations prior to starting each MAVENCLAD treatment course. This page is intended to serve as a summary of that information.

---

*The American Cancer Society recommends that everyone, especially people with chronic illness, have the appropriate cancer screening testing.
IMPORTANT SAFETY INFORMATION (con't)

WARNINGS AND PRECAUTIONS

• **Infections:** MAVENCLAD can reduce the body’s immune defense and may increase the likelihood of infections. Infections occurred in 49% of MAVENCLAD–treated patients compared to 44% of patients treated with placebo in clinical studies. The most frequent serious infections included herpes zoster and pyelonephritis. Single fatal cases of tuberculosis and fulminant hepatitis B were reported in the clinical program. Administer live-attenuated or live vaccines at least 4 to 6 weeks prior to starting MAVENCLAD. Screen patients for latent infections; consider delaying treatment until infection is fully controlled. Vaccinate patients antibody-negative to varicella zoster virus prior to treatment. Administer anti–herpes prophylaxis in patients with lymphocyte counts less than 200 cells per microliter. Monitor for infections. In patients treated with parenteral cladribine for oncologic indications, cases of progressive multifocal leukoencephalopathy (PML) have been reported. No case of PML has been reported in clinical studies of cladribine in patients with MS.

• **Hematologic Toxicity:** In addition to lymphopenia, decreases in other blood cells and hematological parameters have been reported with MAVENCLAD in clinical studies. In general, mild to moderate decreases in neutrophil counts, hemoglobin levels, and platelet counts were observed. Severe decreases in neutrophil counts were observed in 3.6% of MAVENCLAD–treated patients, compared to 2.8% of placebo patients. Obtain complete blood count (CBC) with differential including lymphocyte count before and during treatment, periodically thereafter, and when clinically indicated.

• **Risk of Graft-versus-Host Disease With Blood Transfusions:** Transfusion–associated graft-versus–host disease has been observed rarely after transfusion of nonirradiated blood in patients treated with cladribine for non–MS treatment indications.

• **Liver Injury:** In clinical studies, 0.3% of MAVENCLAD–treated patients had liver injury (serious or causing treatment discontinuation) compared to 0 placebo patients. Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment. Discontinue if clinically significant injury is suspected.

• **Hypersensitivity:** In clinical studies, 11% of MAVENCLAD–treated patients had hypersensitivity reactions, compared to 7% of placebo patients. Hypersensitivity reactions that were serious and/or led to discontinuation of MAVENCLAD, occurred in 0.5% of MAVENCLAD–treated patients, compared to 0.1% of placebo patients. If a hypersensitivity reaction is suspected, discontinue MAVENCLAD therapy. Do not use MAVENCLAD in patients with a history of hypersensitivity to cladribine.

• **Cardiac Failure:** In clinical studies, one MAVENCLAD–treated patient experienced life–threatening acute cardiac failure with myocarditis, which improved after approximately one week. Cases of cardiac failure have also been reported with parenteral cladribine used for treatment indications other than multiple sclerosis.

**Adverse Reactions:** The most common adverse reactions with an incidence of >20% for MAVENCLAD are upper respiratory tract infection, headache, and lymphopenia.

**Drug Interactions/Concomitant Medication:** Concomitant use of MAVENCLAD with immunosuppressive or myelosuppressive drugs and some immunomodulatory drugs (e.g., interferon beta) is not recommended and may increase the risk of adverse reactions. Acute short–term therapy with corticosteroids can be administered. Avoid concomitant use of certain antiviral and antiretroviral drugs. Avoid concomitant use of BCRP or ENT/CNT inhibitors as they may alter bioavailability of MAVENCLAD.

**Use in Specific Populations:** Studies have not been performed in pediatric or elderly patients, pregnant or breastfeeding women. Use in patients with moderate to severe renal or hepatic impairment is not recommended.

For additional information, please click here to view the full Prescribing Information, including boxed WARNING.

REFERENCES

1. Data on File. EMD Serono, Inc.
What would you consider in an MS treatment for a patient experiencing disease activity on her current treatment?

In this real-world patient case study, an MS Specialist evaluated the following issues when choosing a treatment for this patient:

- **Is it effective in my patient’s type of MS?**
- **What are the safety considerations for use in this patient?**
- **Is the dosing schedule appropriate for my patient?**

Please see Important Safety Information throughout this piece, and click here to view accompanying full Prescribing Information, including boxed WARNING.